Oruka Therapeutics (NASDAQ:ORKA) Receives Buy Rating from BTIG Research

Key Points

• Oruka Therapeutics (NASDAQ:ORKA) received a "buy" rating from BTIG Research with a target price of $56.00, indicating a potential upside of 268.42%.
• In addition to BTIG, other analysts have issued positive ratings, with a consensus rating of "buy" and an average price target of $42.00.
• The company has a market capitalization of $569.24 million and has reported a loss of $0.46 earnings per share, which was better than analysts' expectations.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report)'s stock had its "buy" rating reiterated by equities researchers at BTIG Research in a research note issued to investors on Monday,Benzinga reports. They presently have a $56.00 target price on the stock. BTIG Research's target price points to a potential upside of 268.42% from the company's current price.

Several other research analysts have also recently weighed in on ORKA. HC Wainwright reiterated a "buy" rating and issued a $45.00 price target on shares of Oruka Therapeutics in a report on Monday, August 18th. Wedbush reiterated an "outperform" rating and issued a $40.00 price target on shares of Oruka Therapeutics in a report on Tuesday, August 12th. Finally, Wall Street Zen upgraded shares of Oruka Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, September 20th. One investment analyst has rated the stock with a Strong Buy rating and four have given a Buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $42.00.

Oruka Therapeutics Stock Up 1.0%

Oruka Therapeutics stock opened at $15.20 on Monday. The stock has a market capitalization of $569.24 million, a PE ratio of -5.41 and a beta of -0.26. Oruka Therapeutics has a twelve month low of $5.49 and a twelve month high of $31.13. The company has a 50 day moving average of $14.90 and a 200-day moving average of $12.38.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last released its quarterly earnings results on Monday, August 11th. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.02. Equities analysts anticipate that Oruka Therapeutics will post -3.41 EPS for the current fiscal year.

Institutional Trading of Oruka Therapeutics

A number of institutional investors have recently made changes to their positions in ORKA. Legal & General Group Plc bought a new stake in shares of Oruka Therapeutics in the second quarter worth $28,000. Ameritas Investment Partners Inc. bought a new stake in Oruka Therapeutics during the second quarter worth $31,000. BNP Paribas Financial Markets raised its position in Oruka Therapeutics by 464.0% during the second quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company's stock worth $31,000 after acquiring an additional 2,306 shares in the last quarter. Police & Firemen s Retirement System of New Jersey bought a new stake in Oruka Therapeutics during the second quarter worth $68,000. Finally, New York State Common Retirement Fund bought a new stake in Oruka Therapeutics during the second quarter worth $96,000. Institutional investors own 56.44% of the company's stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.